Clinical Trials Logo

Stage IIA Prostate Cancer clinical trials

View clinical trials related to Stage IIA Prostate Cancer.

Filter by:

NCT ID: NCT00121238 Completed - Clinical trials for Recurrent Prostate Cancer

Cilengitide in Treating Patients With Prostate Cancer

Start date: January 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well cilengitide works in treating patients with prostate cancer. Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor

NCT ID: NCT00108732 Completed - Clinical trials for Recurrent Prostate Carcinoma

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Start date: February 2006
Phase: Phase 2
Study type: Interventional

Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Androgens can cause the growth of prostate cancer cells. Drugs, such as bicalutamide and goserelin, may stop the adrenal glands from making androgens in patients whose tumor cells continue to grow. Giving vaccine therapy together with GM-CSF and, when needed, androgen ablation may be a more effective treatment for prostate cancer. This phase II trial is studying how well giving vaccine therapy together with GM-CSF works in treating patients with prostate cancer that progressed after surgery and/or radiation therapy.

NCT ID: NCT00103194 Completed - Clinical trials for Recurrent Prostate Cancer

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

Start date: September 2005
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well lapatinib ditosylate works in treating patients with a rising prostate-specific antigen (PSA), a protein made by the prostate gland, indicating that prostate cancer has come back after previous treatment. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may delay or prevent the progression of prostate cancer.

NCT ID: NCT00003832 Completed - Clinical trials for Stage I Prostate Cancer

Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer

Start date: July 1999
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage I or stage II prostate cancer. Broxuridine may help doctors determine the rate of growth of prostate tumors and help them plan effective treatment